Spotlight On Aldeyra Therapeutics And 2 Other Prominent Penny Stocks
This article highlights three prominent penny stocks—Aldeyra Therapeutics (ALDX), Anavex Life Sciences (AVXL), and Waterdrop (WDH)—that exhibit strong balance sheets and potential for significant returns. Despite challenges like index exclusions for Aldeyra and Anavex, these companies maintain sufficient cash runways or robust financial health, offering opportunities for investors seeking hidden value. Waterdrop, in particular, shows strong revenue generation and earnings growth in the insurance sector.
Spotlight On Aldeyra Therapeutics And 2 Other Prominent Penny Stocks
This article highlights three prominent penny stocks: Aldeyra Therapeutics (ALDX), Anavex Life Sciences (AVXL), and Waterdrop (WDH), emphasizing their financial health and potential for growth despite some challenges. Aldeyra and Anavex are pre-revenue biotechnology companies with sufficient cash runways, while Waterdrop is a profitable online insurance brokerage in China demonstrating strong earnings growth. The piece suggests that these companies offer hidden value for investors looking at quality companies in the penny stock category.
Aldeyra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:137)
This article provides an overview of Aldeyra Therapeutics, Inc. (TRADEGATE:137) including its financial actuals and estimates. It covers analyst price targets, historical stock prices, upcoming earnings reports, and recent financial performance metrics like earnings per share and revenue. The article also touches on company information such as employee count and how to trade its stocks.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX) and its officers. The firm is encouraging Aldeyra shareholders who purchased securities before November 3, 2023, and continue to hold them, to join their investigation. The investigation aims to recover investor capital and ensure corporate accountability, with the firm operating on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aldeyra Therapeutics, Inc. (ALDX) concerning potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who suffered losses between November 3, 2023, and March 16, 2026, have an opportunity to participate and request to be appointed lead plaintiff by May 29, 2026.
Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Value Benchmark
Aldeyra Therapeutics, Inc. (ALDX) has been removed from the Russell 2000 Value Benchmark. This news follows a period of significant activity for the company, including recent appointments to its board, insider share purchases, and a decline in its stock value after the FDA declined to approve its dry eye disease drug, reproxalap. The biotechnology company is focused on developing therapies for immune-mediated and metabolic diseases.
Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) dropped from Russell 2500 Growth Benchmark
Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) has been removed from the Russell 2500 Growth Benchmark as of June 29, 2026. This biotechnology company develops therapies for immune-mediated and metabolic diseases, with product candidates like reproxalap for dry eye disease. The news follows recent announcements regarding board appointments, insider share purchases, and a Complete Response Letter from the FDA for their dry eye drug application.
Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell 3000E Growth Benchmark
Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) has been removed from the Russell 3000E Growth Benchmark. This news follows a period of significant stock performance fluctuation and comes after several announcements regarding board appointments, insider share purchases, and a recent FDA complete response letter for their dry eye disease treatment, which caused a substantial drop in share price. The company is focused on developing therapies for immune-mediated and metabolic diseases, with several product candidates in clinical trials.
Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Dynamic Index
Aldeyra Therapeutics, Inc. (ALDX) has been removed from the Russell 2000 Dynamic Index. This news comes amidst other recent updates for the biotechnology company, including executive appointments, insider share purchases, and a significant setback with the U.S. FDA declining approval for their dry eye disease drug, reproxalap. The company's shares experienced a substantial drop following the FDA decision.
Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 3000 Index
Aldeyra Therapeutics, Inc. (NasdaqCM: ALDX) has been removed from the Russell 3000 Index. The biotechnology company, which focuses on immune-mediated and metabolic diseases, also recently announced the appointment of Darlene Deptula-Hicks to its Board of Directors and reported earnings for the first quarter of 2026. The company's stock has seen significant changes, including a recent downgrade by HC Wainwright and a decline following the US FDA's refusal to approve its dry eye disease drug, Reproxalap.
137 Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Aldeyra Therapeutics, Inc. (137) based on analyst opinions. It includes financial data, past performance, and upcoming earnings information. The company's highest price on record was 13.61 EUR, and the lowest was 1.05 EUR, with the next earnings report due on July 31, 2026.
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (ALDX). The investigation focuses on whether the company and its officers engaged in corporate wrongdoing, specifically for investors who bought securities before November 3, 2023, and still hold them. The firm encourages affected shareholders to contact them to learn more and assist with the investigation.
ALDX Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Aldeyra Therapeutics, Inc. (ALDX) stock for 2027, based on analyst opinions. It includes current stock performance metrics, historical price data, financial insights, and upcoming earnings information. The content emphasizes that this information is not investment advice and encourages users to conduct their own research.
Price to book forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX
This article provides financial information for Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), specifically focusing on its "Price to book forward" metric. The content highlights the company's stock market presence on Nasdaq and offers a brief overview of available financial data.
Price to book forward of Aldeyra Therapeutics, Inc. – DUS:137
This page from TradingView provides financial information for Aldeyra Therapeutics, Inc. (DUS:137), specifically focusing on its "Price to book forward" metric. The content includes navigation to various financial tools, market data, and community features, but the primary article text is minimal. It appears to be a stub or a section of a larger financial data platform.
Price to sales forward of Aldeyra Therapeutics, Inc. – DUS:137
This article provides the "Price to sales forward" value for Aldeyra Therapeutics, Inc. (DUS:137). It indicates the financial data is currently unavailable as the market is closed with no trades recorded. The content functions as a placeholder or an unpopulated financial data page for the company on TradingView.
Enterprise value to revenue forward of Aldeyra Therapeutics, Inc. – DUS:137
This article displays the forward enterprise value to revenue for Aldeyra Therapeutics, Inc. (DUS:137). It shows that the "Period Value" and related "Change" and "Change %" metrics are currently empty, indicating no available data at this time. The data is provided by TradingView, sourcing information from ICE Data Services, FactSet, and Quartr for SEC filings.
Aldeyra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc. (ALDX) stock is currently trading at 1.83 USD, experiencing a -5.26% decrease in the past 24 hours. Analysts predict a future price range of 2.00 USD to 13.00 USD. The company's market capitalization is 108.58M USD, and it will release its next earnings report on July 31, 2026.
Price to earnings forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX
This page from TradingView displays the "Price to earnings forward" for Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). It appears to be a financial data point without further analysis or specific values provided directly on this snippet. The content is primarily a page title within the financial platform.
137 Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for Aldeyra Therapeutics, Inc. (ticker 137 on the Dusseldorf Stock Exchange) based on analyst opinions. It includes details on maximum and minimum price estimates, past price performance, upcoming earnings reports, and financial metrics such as EPS and revenue. The article also addresses frequently asked questions about the company's stock and provides a disclaimer that the information is not investment advice.
Enterprise value to EBIT forward of Aldeyra Therapeutics, Inc. – NASDAQ:ALDX
This article provides financial information for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), specifically focusing on its Enterprise Value to EBIT forward ratio. The content is presented within the context of a financial data platform, indicating the company's market and financial status.
Price to earnings forward of Aldeyra Therapeutics, Inc. – DUS:137
This article displays information related to the price-to-earnings forward metric for Aldeyra Therapeutics, Inc. (stock symbol DUS:137) on the Dusseldorf Stock Exchange. It notes that the market is closed with no trades and provides a structure for viewing financial data, news, and community forecasts related to the company.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) for corporate wrongdoing. The firm is encouraging investors who purchased Aldeyra securities prior to November 3, 2023, and continue to hold them, to join the investigation. The investigation aims to restore investor capital and ensure corporate accountability, with no upfront cost to the investors.
Aldeyra Therapeutics Inc (ALDX) Valuation: PE, PB & Fair Value Analysis
Aldeyra Therapeutics Inc (ALDX) currently has a valuation score of 6.26, ranking 341 out of 387 in the Biotechnology & Medical Research industry. The P/E ratio stands at -3.96. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) securities. The firm is encouraging stockholders who purchased Aldeyra securities prior to November 3, 2023, and still hold them, to assist in their securities investigation regarding potential corporate wrongdoing. The firm operates on a contingency fee basis, only seeking reimbursement if successful in their class action recovery efforts.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aldeyra Therapeutics, Inc. (ALDX) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC represents investors on a contingency fee basis and aims to recover investor capital.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis, only seeking reimbursement if successful in recovering funds for investors.
Aldeyra Therapeutics Inc (ALDX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Aldeyra Therapeutics Inc (ALDX), listing its major shareholders by proportion, categorizing shareholders by type (e.g., Hedge Fund, Investment Advisor), and providing historical institutional shareholding data. Key institutional holders and their recent activity are also presented.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX) and its officers/directors. The firm encourages Aldeyra stockholders who purchased securities before November 3, 2023, and still hold them, to contact them to assist in the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital through securities fraud class actions.
Aldeyra Therapeutics Inc (ALDX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Aldeyra Therapeutics Inc (ALDX) has an earnings forecast score of 8.67, ranking 71st in the Biotechnology & Medical Research industry. Analysts have set an average price target of $9.50 for ALDX, with targets ranging from $7.00 to $13.00, and a majority recommending a "Buy" trend. The company's previous quarter's EPS was -$0.11 against a market expectation of -$0.06, with a -$0.10 EPS expected for the next quarter.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) securities who bought before November 3, 2023, and still hold them. The investigation focuses on whether Aldeyra's officers and/or directors engaged in corporate wrongdoing. The firm encourages affected investors to contact them to assist in the investigation.
Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support
Aldeyra Therapeutics has appointed Darlene Deptula-Hicks as an independent director and Chair of the audit committee following its annual meeting. Shareholders also re-elected CEO Todd C. Brady and ratified BDO USA, P.C. as the independent auditor, signifying continued investor confidence in the company's leadership and governance. Despite these corporate governance developments, a TipRanks AI Analyst rated ALDX stock as Neutral due to weak financial performance and a technically weak price trend.
Aldeyra appoints Darlene Deptula-Hicks to board of directors By Investing.com
Aldeyra Therapeutics has appointed Darlene Deptula-Hicks to its board of directors, leveraging her 30 years of experience in the biotechnology sector. This appointment comes as Aldeyra navigates challenges, including a recent FDA rejection for its dry eye disease treatment and a significant stock price decline, despite analysts maintaining a wide range of price targets and the company holding more cash than debt.
Aldeyra Therapeutics Adds Independent Director, Affirms Governance Support
Aldeyra Therapeutics recently appointed Darlene Deptula-Hicks as a Class III and Chair of the audit committee, a move affirming strong governance. Shareholders also re-elected CEO Todd C. Brady and ratified their independent auditor. Despite this, Spark's AI Analyst gives ALDX a Neutral rating due to weak financial performance, ongoing losses, and a technically weak price trend.
Aldeyra Therapeutics (ALDX) grants board member new stock option awards
Aldeyra Therapeutics (ALDX) announced that board member William D. Clark received two stock option awards as equity compensation. These grants, totaling 72,323 shares with an exercise price of $1.72 per share, have an expiration date of June 8, 2036. The options will become exercisable 100% on the one-year anniversary of the grant date, contingent on Clark's continuous service to the Board of Directors and the Nominating/Corporate Governance Committee.
[Form 4] Aldeyra Therapeutics, Inc. Insider Trading Activity
Aldeyra Therapeutics director Neal Walker received two new stock option grants, according to a Form 4 SEC filing. These grants involve options for 3,318 and 70,000 shares of common stock, both with an exercise price of $1.72 per share. The options become fully exercisable one year after the grant date, contingent on his continuous service on the Board and Compensation Committee.
Aldeyra Therapeutics (ALDX) director Deptula-Hicks submits initial Form 3
Aldeyra Therapeutics director Darlene M. Deptula-Hicks has filed an initial Form 3, establishing her status as a reporting person with the company. This regulatory filing indicates her beneficial ownership for insider purposes but does not report any stock transactions or option exercises. The Form 3 clarifies that Deptula-Hicks is a director of Aldeyra Therapeutics and holds no derivative securities or has engaged in any buying or selling of ALDX shares as part of this initial statement.
Aldeyra Therapeutics (ALDX) director receives new stock option awards
Aldeyra Therapeutics director Gary M. Phillips has received three new stock option grants, allowing him to purchase 70,000, 6,636, and 4,977 shares of common stock at an exercise price of $1.72 per share. These options will become fully exercisable on the one-year anniversary of the grant date, provided he continues his service on the Board and its Compensation and Audit Committees. The grants are compensation for his roles and are set to expire on June 8, 2036.
Aldeyra Therapeutics CEO, President & Director Acquires 18% More Stock
Aldeyra Therapeutics CEO, Todd Brady, recently purchased US$418k worth of company stock at US$1.67 per share, increasing his holding by 18%. This purchase was the largest insider buy in the last year, indicating optimism among company leadership. While insider ownership is only 3.6%, recent buying trends suggest insiders
What Does Darlene Deptula-Hicks Bring to Aldeyra's Board
Aldeyra Therapeutics' appointment of Darlene Deptula-Hicks to its Board of Directors is a strategic move to enhance financial stewardship and aid potential commercialization, especially following the March 2026 Complete Response Letter for reproxalap. Ms. Deptula-Hicks' extensive background in biotech IPOs, capital raising, and M&A, coupled with her experience as a CFO, is crucial for Aldeyra's future funding and growth, as the company faces regulatory hurdles, a shrinking workforce, and the need for significant capital to advance its pipeline. Her expertise will be vital in navigating the complexities of commercializing reproxalap and other therapies despite the current operational and financial challenges.
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
Aldeyra Therapeutics, a biotechnology company focused on immune-mediated diseases, has appointed Darlene Deptula-Hicks to its board of directors. Ms. Deptula-Hicks brings over 30 years of experience in the life sciences sector, including senior executive and CFO roles in public and private companies. Her expertise in capital raises, strategic partnerships, and M&A transactions is expected to support Aldeyra as it moves towards potential commercialization of its therapies.
Aldeyra appoints Darlene Deptula-Hicks to board of directors
Aldeyra Therapeutics, Inc. has appointed Darlene Deptula-Hicks to its board of directors, leveraging her 30 years of biotechnology experience for potential commercialization efforts. This appointment comes amidst recent challenges for Aldeyra, including a loan repayment, an FDA rejection for its dry eye disease treatment, and a downgrade from H.C. Wainwright, though BTIG maintained a Buy rating. The company's shares are down 67% year-to-date, indicating a period of significant transition.
Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock
Aldeyra Therapeutics CEO Todd C. Brady recently purchased 250,000 shares of the company's common stock for a total of $418,450. This insider acquisition follows a significant 62.55% decline in the stock over the past six months and comes after the FDA rejected their dry eye disease treatment. Despite regulatory setbacks, the stock appears undervalued according to InvestingPro analysis, and one analyst firm has maintained a "Buy" rating.
Aldeyra (NASDAQ: ALDX) CEO Todd Brady purchases 250,000 common shares
Aldeyra Therapeutics, Inc.'s President and CEO, Todd C. Brady, recently purchased 250,000 shares of the company's common stock in an open-market transaction on June 3, 2026. The shares were acquired at a weighted average price of $1.6738, ranging from $1.64 to $1.70 per share, increasing his direct ownership to 1,721,298 shares. This insider purchase signals positive sentiment and confidence from the CEO in the company's future.
Aldeyra Therapeutics Insider Bought Shares Worth $418,450, According to a Recent SEC Filing
An insider at Aldeyra Therapeutics recently purchased shares amounting to $418,450, according to a new SEC filing. The company (ALDX) is a biotechnology firm focused on developing therapies for immune-mediated and metabolic diseases, with product candidates like reproxalap and ADX-629. This transaction follows other recent company news, including first-quarter earnings and a recent FDA decision regarding one of its drug applications.
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
Aldeyra Therapeutics is awaiting critical feedback from the FDA regarding its dry eye disease drug candidate, reproxalap, after receiving a third complete response letter. CEO Todd Brady indicated the company would pursue a Type A meeting to discuss the rejection, focusing on demonstrating the "totality" of evidence for approval without needing an additional trial. If the FDA does not reconsider, Aldeyra plans to appeal through the Formal Dispute Resolution Request process.
3 Promising Penny Stocks With Market Caps Reaching $300M
This article identifies three penny stocks—Aldeyra Therapeutics (ALDX), Broadwind (BWEN), and Zhihu (ZH)—highlighting their financial health and market position. While these companies face typical penny stock challenges like volatility and unprofitability, they also show potential for growth due to factors like sufficient cash runways, strategic maneuvers, or improving financial metrics. The analysis aims to help investors discover hidden value in these smaller companies through detailed financial breakdowns.
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Aldeyra Therapeutics (ALDX) will participate in the 2026 Jefferies Global Healthcare Conference. Chief Executive Officer Todd Brady, M.D., Ph.D., is scheduled to present on Wednesday, June 4, 2026, at 2:30 p.m. ET. A live audio webcast of the presentation will be available on the company's website, with an archived replay accessible for approximately 30 days.
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
Aldeyra Therapeutics announced that its President and CEO, Todd C. Brady, M.D., Ph.D., will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The event is scheduled for June 4, 2026, at 8:45 a.m. ET, and a live webcast will be available via the company's investor relations website. Aldeyra Therapeutics is a biotechnology company focused on developing innovative therapies for immune-mediated diseases.
